Skip to main content
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Vor Biopharma Inc. - Common Stock (NQ:VOR)

29.57 +0.51 (+1.75%)
Streaming Delayed Price Updated: 2:05 PM EDT, Oct 17, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 471,781
Open 28.66
Bid (Size) 29.40 (1)
Ask (Size) 29.70 (2)
Prev. Close 29.06
Today's Range 28.65 - 31.31
52wk Range 2.622 - 65.80
Shares Outstanding 66,956,800
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Vor Bio Announces Late-Breaking Oral Presentation of China Phase 3 IgA Nephropathy Clinical Study at American Society of Nephrology’s Kidney Week 2025
From Vor Biopharma
Via GlobeNewswire
Novartis Strengthens Kidney Disease Pipeline With Promising Data
Novartis' Fabhalta showed significant efficacy and safety in a Phase 3 IgA nephropathy study, supporting regulatory filings planned for 2026. 
Via Benzinga

Performance

YTD
+32.0%
+32.0%
1 Month
-5.8%
-5.8%
3 Month
-37.9%
-37.9%
6 Month
+127.5%
+127.5%
1 Year
+118.9%
+118.9%

More News

Read More
Vor Bio Announces Publication of China Phase 3 Study of Telitacicept in Systemic Lupus Erythematosus in The New England Journal of Medicine
From Vor Biopharma
Via GlobeNewswire
Vor Bio Stock Jumped 19% Today And Retail Investors Are Eyeing A Breakout Rally: Here’s What’s Happening
Via Stocktwits
Vor Bio's Collaborator Delivers Positive Results For Telitacicept In Autoimmune Disorder That Impacts Tears
Via Benzinga
Telitacicept Demonstrates Clinically Meaningful and Statistically Significant Impact on ESSDAI Compared to Placebo in Late-Breaking China Phase 3 Results in Primary Sjögren’s Disease at ACR 2025
From Vor Biopharma
Via GlobeNewswire
Vor Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Vor Biopharma
Via GlobeNewswire
12 Health Care Stocks Moving In Wednesday's Intraday Session
Via Benzinga
12 Health Care Stocks Moving In Tuesday's Intraday Session
Via Benzinga
Vor Bio Announces Late-Breaking Poster Presentation of Phase 3 Primary Sjögren’s Disease Clinical Study at ACR Convergence 2025
From Vor Biopharma
Via GlobeNewswire
Vor Bio Appoints Navid Z. Khan, Ph.D., as Chief Medical Affairs Officer
From Vor Biopharma
Via GlobeNewswire
Vor Bio Announces Oral Presentation of 48-Week China Phase 3 Generalized Myasthenia Gravis Clinical Study at AANEM
From Vor Biopharma
Via GlobeNewswire
Vor Bio to Participate in the Stifel 2025 Virtual Immunology and Inflammation Forum
From Vor Biopharma
Via GlobeNewswire
Vor Bio Appoints Adi Osovsky, S.J.D. as General Counsel
From Vor Biopharma
Via GlobeNewswire
FDA Eases Monitoring Burden For Kidney Disease Patients On Travere Therapeutics' Filspari
Via Benzinga
Vor Bio's Investigational Drug Scores Phase 3 Win In Autoimmune Kidney Disease Trial
Via Benzinga
Telitacicept Achieved Primary Endpoint in Phase 3 Clinical Study for IgA Nephropathy
From Vor Biopharma
Via GlobeNewswire
Vor Bio to Participate in Upcoming Investor Conferences
From Vor Biopharma
Via GlobeNewswire
Vor Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Vor Biopharma
Via GlobeNewswire
Vor Bio Rallies On Strong Data For Autoimmune Drug Candidate
Via Benzinga
Telitacicept Achieved Primary Endpoint in Phase 3 Clinical Study for Primary Sjögren's Disease with Telitacicept, a Dual BAFF/APRIL Inhibitor
From Vor Biopharma
Via GlobeNewswire
Vor Bio Appoints Seasoned Biotech Executive Dallan Murray as Chief Commercial Officer
From Vor Biopharma
Via GlobeNewswire
Vor Bio Appoints Biotech Industry Leaders Alexander (Bo) Cumbo and Michel Detheux, Ph.D. to Board of Directors
From Vor Biopharma
Via GlobeNewswire
Vor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
From Vor Biopharma
Via GlobeNewswire
Vor Bio Appoints Qing Zuraw, M.D. as Chief Development Officer
From Vor Biopharma
Via GlobeNewswire

Frequently Asked Questions

Is Vor Biopharma Inc. - Common Stock publicly traded?
Yes, Vor Biopharma Inc. - Common Stock is publicly traded.
What exchange does Vor Biopharma Inc. - Common Stock trade on?
Vor Biopharma Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Vor Biopharma Inc. - Common Stock?
The ticker symbol for Vor Biopharma Inc. - Common Stock is VOR on the Nasdaq Stock Market
What is the current price of Vor Biopharma Inc. - Common Stock?
The current price of Vor Biopharma Inc. - Common Stock is 29.57
When was Vor Biopharma Inc. - Common Stock last traded?
The last trade of Vor Biopharma Inc. - Common Stock was at 10/17/25 02:05 PM ET
What is the market capitalization of Vor Biopharma Inc. - Common Stock?
The market capitalization of Vor Biopharma Inc. - Common Stock is 1.98B
How many shares of Vor Biopharma Inc. - Common Stock are outstanding?
Vor Biopharma Inc. - Common Stock has 2B shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.